Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-08T17:34:53.012Z Has data issue: false hasContentIssue false

Profiling inflammatory cytokines following zinc supplementation: a systematic review and meta-analysis of controlled trials

Published online by Cambridge University Press:  20 January 2021

Amir Hossein Faghfouri
Affiliation:
Department of Community Nutrition, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
Behzad Baradaran
Affiliation:
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Alireza Khabbazi
Affiliation:
Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Yaser Khaje Bishak
Affiliation:
Department of Nutrition, Maragheh University of Medical Sciences, Maragheh, Iran
Meysam Zarezadeh
Affiliation:
Nutrition Research Center, Department of Clinical Nutrition, Student Research Committee, School of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran
Omid Mohammad Tavakoli-Rouzbehani
Affiliation:
Nutrition Research Center, Department of Clinical Nutrition, School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
Elnaz Faghfuri
Affiliation:
Digestive Disease Research Center, Ardabil University of Medical Sciences, Ardabil, Iran
Laleh Payahoo
Affiliation:
Department of Nutrition, Maragheh University of Medical Sciences, Maragheh, Iran
Maedeh Alipour
Affiliation:
Medical Student, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Beitullah Alipour*
Affiliation:
Department of Community Nutrition, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
*
*Corresponding author: Beitullah Alipour, email [email protected]
Rights & Permissions [Opens in a new window]

Abstract

Chronic inflammation has been considered as the main cause of chronic diseases. Zn has anti-inflammatory effects by decreasing the expression of inflammatory markers. The present systematic review and meta-analysis study aims to evaluate the impact of Zn supplementation on inflammation. PubMed (Medline), Scopus, Web of Science, and Embase databases were searched up to 10 December 2020. Controlled trials which have investigated the effects of Zn supplementation on serum/plasma levels of inflammatory cytokines in subjects aged >15 years were included. A pooled meta-analysis was performed using a random effect model. Sensitivity analysis was performed to determine the robustness of the observed effect sizes. A total of twelve studies was included in meta-analysis. Zn could decrease IL-6 levels (standardised mean difference (SMD) = −0·76 pg/ml; 95 % CI −1·28, −0·24; P = 0·004). There was no significant change in TNF-α (SMD = 0·42 pg/ml; 95 % CI −0·31, 1·16; P = 0·257) and IL-2 levels (SMD = 1·64 pg/ml; 95 % CI −1·31, 4·59; P = 0·277) following Zn supplementation. However, Zn could increase IL-2 significantly after the deletion of one arm in sensitivity analysis (SMD = 2·96 pg/ml; 95 % CI 2·03, 3·88; P < 0·05). Conclusively, Zn supplementation can decrease the IL-6 level. Zn increased IL-2 level after the sensitivity analysis. Zn supplementation has not ameliorative effects on TNF-α.

Type
Systematic Review and Meta-Analysis
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Nutrition Society

Inflammation is a multifactorial network of chemical signals in response to detrimental insults such as tissue injury, other noxious conditions and microbial infection. It is a critical immune response by the host that removes the harmful stimuli as well as the healing of the damaged tissue(Reference Ahmed1). Normal inflammation usually limits itself; however, dysregulation in any inflammatory factors can lead to abnormalities and pathogenesis. Systematic inflammation is believed to be associated with the initiation and progression of various chronic conditions such as cerebrovascular disease, dementia, ischemic heart and respiratory disease(Reference McLoughlin, Berthon and Jensen2). Also, the inflammatory response plays a vital role in different stages of tumour development, including initiation, progression, conversion to malignant and metastasis(Reference Grivennikov, Greten and Karin3).

The inflammatory processes involve activation of the immune system, directed migration of leucocytes, and release of pro-inflammatory cytokines and mediators(Reference Schwingshackl and Hoffmann4). Cytokines are molecules with glycoprotein or protein structure that affect interactions and communication between cells(Reference Zhang and An5). Among the various type of cytokines, TNF-α, IL-2, IL-6 and IL-1 are significant inducers of the acute-phase response(Reference Derosa, Maffioli and Simental-Mendia6,Reference Coussens and Werb7) . TNF-α through binding to its receptor (TNFR1 and TNFR2) regulates the cytokine cascade in inflammatory pathways as well as cell proliferation, survival, differentiation and apoptosis of immune cells(Reference Parameswaran and Patial8). IL-2 acts as both inflammatory and anti-inflammatory agent via binding to its receptor, and regulation of these dual effects is important in the treatment of many inflammatory diseases(Reference Banchereau, Pascual and O’Garra9). Membrane IL-6 receptor (mIL-6 R) mediates IL-6 actions including the differentiation and maturation of immune cells and the induction of acute-phase protein synthesis in hepatocytes(Reference Tanaka, Narazaki and Kishimoto10).

Production of these cytokines is mediated by different transcription factors (TF) including NF-κB, CCAAT/enhancer-binding protein (C/EBP)-β, the activator protein 1 (AP-1) and the nuclear factor of activated T cells(Reference Vaeth and Feske11Reference Luo and Zheng14). Zn, as a trace element, plays an important role in the stabilisation of TF through Zn finger proteins(Reference Cassandri, Smirnov and Novelli15). A number of in vivo and in vitro studies have demonstrated that Zn can be effective in the regulation of mentioned TF, whereby it regulates inflammatory cascades(Reference Bao, Prasad and Beck16Reference Kim, Aydemir and Cousins19).

Despite the number of trials which have investigated the effect of Zn supplementation on diseases associated with ongoing inflammation(Reference Jamilian, Foroozanfard and Bahmani20,Reference Khazdouz, Mazidi and Ehsaei21) as well as diabetes(Reference Cruz, de Oliveira and do Nascimento Marreiro22) and atherosclerosis(Reference Dias, Sena-Evangelista and de Oliveira Paiva23), there is no comprehensive systematic review and meta-analysis to obtain a conclusive finding on the impact of Zn supplementation on cytokines. Therefore, this systematic review and meta-analysis study is conducted to evaluate the potential anti-inflammatory effects of Zn supplementation.

Material and methods

Search strategy

This systematic review and meta-analysis study was performed and reported in accordance with the guiding principle and recommendation of the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA)(Reference Moher, Liberati and Tetzlaff24). PubMed (Medline), Scopus, Web of Science and Embase databases were searched up to 10 December 2020 by three authors (M. Z., Y. K. H. and A. H. F.) independently with no limitation for year and language. Search was performed by using following search pattern: (‘Zinc’ [Mesh] OR zinc[Title/Abstract]) AND (Interleukin-8[Title/Abstract] OR IL-8[Title/Abstract] OR CXCL8[Title/Abstract] OR NAP[Title/Abstract] OR NAP1[Title/Abstract] OR IL-2[Title/Abstract] OR interleukin-2[Title/Abstract] OR Interleukin-1[Title/Abstract] OR IL-1[Title/Abstract] OR Interleukin-1beta[Title/Abstract] OR Interleukin-1β[Title/Abstract] OR IL-1 β [Title/Abstract] OR IL-1beta[Title/Abstract] OR ‘Interleukin-2’ [Mesh] OR ‘Interleukin-1beta’ [Mesh] OR ‘Interleukin-8’ [Mesh] OR ‘Tumor Necrosis Factor-alpha’ [Mesh] OR tumor necrosis factor-alpha[Title/Abstract] OR TNF[Title/Abstract] OR ‘tumor necrosis factor’ [Title/Abstract] OR ‘tumor necrosis factor-α’ [Title/Abstract] OR tnf-alpha[Title/Abstract] OR tnf- α[Title/Abstract] OR tnfα[Title/Abstract] OR Tumour necrosis factor[Title/Abstract] OR ‘Interleukin-6’ [Mesh] OR interleukin-6[Title/Abstract] OR IL-6[Title/Abstract] OR interleukin6[Title/Abstract] OR IL6[Title/Abstract] OR inflammation[Title/Abstract]) AND (randomized controlled trial[Publication Type] OR controlled clinical trial[Publication Type] OR ‘clinical trial’ [Title/Abstract] OR random * [Title/Abstract] OR supplementation[Title/Abstract] OR placebo[Title/Abstract] OR groups[Title/Abstract] OR trial[Title/Abstract] OR ‘randomized controlled trial’ [Title/Abstract] OR ‘controlled clinical trial’ [Title/Abstract]. We used the wild-card term ‘*’ to increase the search sensitivity.

Study selection and inclusion and exclusion criteria

After removing duplicate records, the titles and abstracts of the searched studies were screened based on the inclusion and exclusion criteria by three authors (O. M. T. R., E. F. and M. A.) independently. Controlled trials with parallel or cross-over design which have investigated the effects of Zn supplementation on the inflammatory cytokines were included. The PICO strategy for the research question of the study was Patient/Population (P): subjects with age of ≥15 years; Intervention (I): oral supplementation with Zn; Comparison (C): placebo or control group; and Outcome (O): changed TNF-α, IL-2 or IL-6 serum/plasma levels. Exclusion criteria were considered as follows: (i) other types of studies (in vitro, in vivo, ex vivo, quasi-experimental, reviews, letters, conference abstracts, case reports and observational studies), (ii) Zn supplementation along with another ingredient, (iii) infants and juvenile subjects, and (iv) lack of adequate information. Also, the reference lists of included studies were evaluated for other potential articles.

Data extraction

Articles meeting the inclusion criteria were abstracted by two authors (A. H. F. and L. P.) independently on the following items: first author and year of publication, journal, the region of investigation, sample size in each group, sex of subjects, mean age of subjects in each group, administered dosage and form of Zn, duration of treatment, and serum/plasma levels of inflammatory markers before and after the trial in each group. Any disagreements were discussed and resolved with a third reviewer (B. A.).

Study quality assessment

The Cochrane Collaboration tool was used for quality assessment of each trial included by two authors(Reference Higgins, Altman and Gøtzsche25). This tool assesses random sequence generation, allocation concealment details, blinding, elucidating of dropouts, reporting bias and other possible causes of bias. Each parameter was reported as high (−) or low (+) risk of bias, and unclear (?).

Statistical analysis

All data in included studies were reported as mean ± standard deviation. Reported means and standard errors, medians and ranges, and medians and interquartile ranges (Q25–Q75) were converted to means and standard deviations with statistical calculations. Pooled effect sizes were calculated using a random effect model with restricted maximum likelihood method. Because of the homogenised measurement units, the pooled effect sizes were expressed as standardised mean differences (SMD) with 95 % CI. I 2 statistic was used for the assessment of between-study heterogeneity and I 2 > 50 % was reported as high heterogeneity(Reference Higgins, Thompson and Deeks26). Potential sources of heterogeneity were identified using meta-regression and subgroup analysis based on sex, administered Zn dosage and form, duration, study population, and mean age. In meta-regression analysis, any linear relationship between the effect sizes and intervention duration, dose, and sample size were assessed. The influence of single study removal on the pooled effect size was assessed using sensitivity analysis. Publication bias was assessed using visual inspection of the funnel plot. In the presence of funnel plot’s asymmetry, the trim and fill method was carried out for adjusting the results with estimating the missing studies that might exist in pooled analysis and the effect of these studies on the outcome. Small-study effects were investigated using Begg’s adjusted rank correlation and Egger’s regression asymmetry tests(Reference Begg and Mazumdar27,Reference Egger, Davey Smith and Schneider28) . In all tests, P < 0·05 was considered as significant level. All statistical analyses were performed using STATA version 16.0 (Stata Corporation).

Results

Study selection

Totally, 10 676 articles were obtained from a search in databases. Titles and abstracts of 7545 studies were screened after eliminating duplicate articles. Among which, 178 articles were eligible for assessing full texts. Finally, a total of twelve articles met the inclusion criteria and included in the quantitative synthesis. PRISMA flow chart for literature search and selection is presented in Fig. 1.

Fig. 1. The process of study selection through stages shown by Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) flow chart. RCT, randomised controlled trial.

Characteristics of selected studies

Among included studies, eight studies with nine treatment arms, eight studies with eight treatment arms and two studies with three treatment arms investigated the effect of Zn supplementation on TNF-α, IL-6 and IL-2 levels, respectively. Four of the included studies were performed in Iran(Reference Ranjbar, Shams and Sabetkasaei29Reference Roshanravan, Tarighat-Esfanjani and Alamdari32). Other studies have been carried out in Turkey(Reference Kara, Ozal and Gunay33), Brazil(Reference de Moura, Soares and de Lima Barros34), Russia(Reference Freiberg, Cheng and Gnatienko35), Australia(Reference Foster, Petocz and Samman36), Thailand(Reference Meksawan, Sermsri and Chanvorachote37), USA(Reference Bao, Prasad and Beck38) South Korea(Reference Kim and Ahn39) and Poland(Reference Suliburska, Skrypnik and Szulińska40) with a total sample size of 680 (varied from 17 to 254 participants). The included studies were performed from 2010 to 2020. The mean age of subjects ranged between 15 and 67 years. The Zn salts gluconate and sulphate were used in the included studies which provided 12–50 mg/d of elemental Zn. The duration of supplementation was between 4 and 72 weeks. Participants of four studies were chosen from females and others from both sexes. Inflammatory cytokines in five and seven studies were measured in serum and plasma, respectively. Characteristics of included studies are outlined in Table 1.

Table 1. Characteristics and baseline measurements of included studies

(Mean values and standard deviations)

INT, intervention group; CONT, control group; NR, not reported; Sulph, sulphate; Gluc, gluconate; F, female; M, male; PW, postmenopausal women; PCOS, polycystic ovary syndrome; IGT, impaired glucose tolerance.

* From the same studies with investigating Zn supplementation on different subjects.

Expressed as range.

Risk of bias assessment

The results of Cochrane Collaboration’s tool on the assessment of the risk of bias are presented in Fig. 2. As shown, random allocation was not observed in one included study. Moreover, the intention to treat protocol for analysing data in trials was not performed in four included studies. Four included studies had higher quality compared with others.

Fig. 2. The result of risk of bias assessment using Cochrane Collaboration’s risk of bias tool: each risk of bias item for included studies (green (+) means low risk of bias, yellow (?) means unclear risk of bias, red (−) means high risk of bias).

Effects of zinc on TNF-α

Zn supplementation had not a significant effect on TNF-α level in pooled estimate (SMD = 0·42 pg/ml; 95 % CI −0·31, 1·16; P = 0·257) (Fig. 3(a)). This result was confirmed by sensitivity analysis. However, the gluconate form of Zn supplement led to a significant decrease in TNF-α level following subgroup analysis (SMD = −0·89 pg/ml; 95 % CI −1·35, −0·43; P < 0·001) (Table 2). Moreover, TNF-α reduction was shown following <40 mg/d elemental Zn supplementation (SMD = −0·37 pg/ml; 95 % CI −0·74, −0·00; P = 0·048). However, ≥40 mg/d elemental Zn supplementation resulted in a significant increase in TNF-α serum/plasma level (SMD = 2·73 pg/ml; 95 % CI 0·08, 5·39; P = 0·044). There was a significant between-study heterogeneity (I 2 = 87·9 %, P < 0·001), which was reduced with subgrouping by the mean age of participants, Zn salt, study population and duration (Table 2). Meta-regression analysis showed that the effect size had no significant relationship with duration, mean age and sample size. Begg’s test did not confirm the presence of a small-study effect (P = 0·118). However, a significant small-study effect was shown following Egger’s test (P = 0·02). Moreover, visual inspection showed an asymmetric distribution in the funnel plot (Fig. 3(b)). However, trim and fill analysis confirmed the observed result (SMD = 0·98 pg/ml; 95 % CI −1·37, 3·34; P > 0·05).

Fig. 3. Forest plot (a) detailing standardised mean differences (SMD) and 95 % confidence intervals and funnel plot (b) displaying publication bias in the studies reporting the effects of zinc supplementation on TNF-α level.

Table 2. Pooled estimates of effects of zinc on inflammatory markers within different subgroups

(Standard mean differences (SMD) and 95 % confidence intervals)

F, female; M, male; NR, not recognised.

Effects of zinc on IL-2

Pooled analysis revealed that Zn supplementation had no significant effect on IL-2 level (SMD = 1·64 pg/ml; 95 % CI −1·31, 4·59; P = 0·277) (Fig. 4(a)). However, sensitivity analysis revealed that removing Beserra de Moura et al. study(Reference de Moura, Soares and de Lima Barros34) in pooled analysis led to a significant increase in IL-2 level following Zn supplementation (SMD = 2·96 pg/ml; 95 % CI 2·03, 3·88; P <  0·05). Because of limited number of studies on IL-2, subgroup analysis and meta-regression were not possible. Egger’s test but not Begg’s test showed publication bias due to small-study effects (P = 0·024 and P = 0·296, respectively). Moreover, visual inspection of the funnel plot illustrated the asymmetric distribution of studies (Fig. 4(b)). However, trim and fill analysis with three observed studies confirmed the observed results (SMD = 1·55 pg/ml; 95 % CI −0·97, 4·08; P > 0·05).

Fig. 4. Forest plot (a) detailing standardised mean differences (SMD) and 95 % confidence intervals and funnel plot (b) displaying publication bias in the studies reporting the effects of zinc supplementation on IL-2 level.

Effects of zinc on IL-6

The results of forest plot showed that Zn supplementation could decrease IL-6 level (SMD = −0·76 pg/ml; 95 % CI −1·28, −0·24; P = 0·004) (Fig. 5(a)). Duration of supplementation, study population and administered dosage were recognised as sources of observed high between-study heterogeneity (I 2 = 85·1 %, P < 0·001) (Table 2). Also, subgroup analysis revealed that a higher dosage of Zn supplements (≥40 mg/d), female sex, healthy population and higher mean age (>40 years) resulted in a more reduction of IL-6 levels (Table 2). Among Zn forms, zinc gluconate had an ameliorative effect on the IL-6 level (Table 2). Meta-regression analysis revealed no significant relationship between the effect size and intervention duration, dose, and sample size. There were no small-study effects following Egger’s and Begg’s tests (P = 0·181 and 0·108, respectively). Moreover, symmetric distribution of studies was visualised in the funnel plot (Fig. 5(b)).

Fig. 5. Forest plot (a) detailing standardised mean differences (SMD) and 95 % confidence intervals and funnel plot (b) displaying publication bias in the studies reporting the effects of zinc supplementation on IL-6 level.

Discussion

As our knowledge, this systematic review and meta-analysis study is the first comprehensive investigation evaluated the possible effects of Zn supplementation on serum/plasma profile of inflammatory cytokines including IL-2, IL-6 and TNF-α using published trial data. We revealed that Zn supplementation had an ameliorative effect on the IL-6 level. Zn forms, dosage, intervention duration, study population and mean age of participants could affect the pooled estimate and considered as the potential sources of heterogeneity. We did not include C-reactive protein (CRP) level in our meta-analysis since other meta-analysis study by Mousavi et al. revealed that Zn supplementation could decrease CRP level(Reference Mousavi, Djafarian and Mojtahed41).

We demonstrated that Zn supplementation had no ameliorative effect on TNF-α level following pooled analysis of nine relevant studies. Subgroup analysis revealed that intervention duration, study population, mean age of participants and Zn forms of the supplement were potential sources of high heterogeneity. Duration of supplementation and the mean age of participants were from a broad range, and these could cause various results. Analysis of two studies that administered the gluconate form revealed that zinc gluconate had a beneficial effect on the TNF-α level. One possible cause is difference in bioavailability. Sapota et al. revealed that the rats administered zinc sulphate had the lowest Zn in the prostate tissue compared with those supplemented with zinc gluconate(Reference Sapota, Daragó and Skrzypińska-Gawrysiak42). On the other hand, another in vivo study reported that zinc gluconate and zinc sulphate had equivalent bioavailability(Reference Zhang, Yu and Zhang43). The second cause is study population; in one study administered zinc gluconate, subjects had Zn deficiency(Reference de Moura, Soares and de Lima Barros34). It seems Zn supplementation had a more beneficial effect on inflammatory markers in the Zn deficiency status. In the other study, subjects were obese persons who had altered Zn redistribution(Reference Kim and Ahn39). Surprisingly, Zn supplementation increased TNF-α level in higher dosages (≥40 mg/d elemental Zn) subgroup and decreased TNF-α level in lower dosage (<40 mg/d elemental Zn). The tolerable upper intake level of Zn for adults has been determined 40 mg/d(44). Zn acts as a pro-oxidant agent in overload condition through disrupting of mitochondria homoeostasis and excessive reactive oxygen species production(Reference Lee45). Moreover, Zn toxicity might be related to increase in pro-inflammatory cytokine production(Reference Plum, Rink and Haase46).

We failed to find a significant association between Zn supplementation and the IL-2 production in the pooled estimate. However, sensitivity analysis revealed that Zn supplementation led to a significant increase in IL-2 level after omitting Beserra de Moura et al. study(Reference de Moura, Soares and de Lima Barros34). The intervention groups in the mentioned study were subjects with Zn deficiency in whom their serum Zn levels were not raised enough to reach Zn sufficiency status during the supplementation, likely because of short duration and low dosage of intervention. Since IL-2 production is impaired in Zn-deficient subjects(Reference Prasad, Beck and Kaplan47), their IL-2 levels remained low. IL-2 reduction in Zn deficiency status is related to the expression of the TF cAMP-responsive element modulator α (CREMα) which is involved in IL-2 transcription. CREMα binding site is cAMP-responsive element which is located within the IL-2 promoter. Therefore, its high expression inhibits IL-2 transcription(Reference Kloubert, Wessels and Wolf48). In vitro investigation revealed that Zn deficiency increased CREMα expression(Reference Kloubert, Wessels and Wolf48).

IL-2 has dual effects on inflammatory pathways. It is a promoter of T-cell proliferation and T-helper 1 (Th1) and Th2 effector cells generator and whereby induces inflammation. On the other hand, IL-2 inhibits the production of inflammatory Th17 cells and has a pivotal role in regulatory T-cell maintenance(Reference Hoyer, Dooms and Barron49). In lower dosage, IL-2 has been used as a therapeutic agent in the various types of cancer and inflammatory conditions because of its effect on immune system function and anti-inflammatory impacts in lower dosage(Reference Banchereau, Pascual and O’Garra9,Reference Shachar and Karin50) . However, in higher dosage, IL-2 may lead to toxicity and inflammation in some organs like skin and lung(Reference Shachar and Karin50). It is not known whether observed increase in IL-2 concentration in our meta-analysis has inflammatory effects or anti-inflammatory. It must be noted that participants of included studies in our meta-analysis on the effect of Zn treatment on IL-2 level were from people with a low concentration of serum/plasma Zn. Moreover, other ex vivo studies revealed that Zn supplementation had increasing effect on IL-2 production in Zn-deficient subjects(Reference Prasad, Beck and Kaplan47,Reference Rahfiludin, Wirjatmadi and Agusni51) . Therefore, it seems that Zn supplementation corrected the low level of IL-2 as an anti-inflammatory agent.

Nine comparisons of eight relevant studies revealed that Zn supplementation could decrease the IL-6 level. Intervention duration, dosage, study population and Zn forms were potential sources of high heterogeneity. Similar to TNF-α pooled analysis, intervention duration and elemental Zn dosage were from a broad range: 12–50 mg/d and 8–72 weeks, thereby they could cause heterogeneity in the results. Higher dosage of elemental Zn (≥40 mg/d), gluconate form and older subgroups had more decrease of IL-6 serum/plasma level. As discussed above, more beneficial effect of gluconate form may be related to its better bioavailability. Elderly people are more at risk for chronic inflammation and oxidative stress than younger people(Reference Prasad, Bao and Beck52). As a result, Zn supplementation seems to have a more beneficial effect on inflammation in the elderly subjects than in the young. Higher dosage of Zn had different impacts on TNF-α and IL-6 levels. TNF-α is an early response cytokine(Reference Mizgerd, Spieker and Doerschuk53,Reference Andreasen, Krabbe and Krogh-Madsen54) . Pro-oxidant conditions, caused by Zn overload, firstly elevate TNF-α level. It seems that a long-term supplementation with a high dosage of Zn is needed to have an increasing effect on IL-6 levels. The results on healthy and patient subjects were not very different, and more studies on people with different health statuses are needed to draw the right conclusion. Bao et al. study(Reference Bao, Prasad and Beck38) was the only study with higher baseline plasma Zn. However, sensitivity analysis revealed that omission of mentioned study did not change the overall result.

Zn has a possible effect on IL-2, IL-6 and TNF-α levels through the regulation of NF-ĸB activation. Dimerisation of NF-ĸB mediated by other subunits like p50, p65, c-Rel and RelB is essential for its binding to DNA(Reference Giuliani, Bucci and Napolitano55). Zn finger proteins like A20, growth factor independence-1 (Gfi-1), Zn finger and BTB domain containing 20 (ZBTB20), and Zn finger protein-64 (ZFP-64) are involved in NF-ĸB signalling; as A20 and Gfi-1 inhibit NF-ĸB dimerisation; ZBTB20 and ZFP-64 promote NF-ĸB dimerisation(Reference Faghfouri, Zarrin and Maleki56). It has been found that Zn supplementation induces A20 binding to mRNA and DNA via the upregulation of mRNA and DNA-specific sites and whereby acts its anti-inflammatory effect(Reference Prasad, Bao and Beck52). In an in vivo study, Zn was contributed to the reduction of NF-κB p65 mRNA expression in the jejunum of weaned piglets(Reference Hu, Cheng and Li57). Moreover, stabilisation of other TF including CCAAT/enhancer-binding protein (C/EBP)-β, AP-1 and nuclear factor of activated T cells which are contributed in the production of cytokines is mediated by Zn. Zn status also can be effective in mRNA expression of a cytokine through binding to metal response elements on the promoter of target genes(Reference Bao, Prasad and Beck58,Reference Cousins59) .

Some limitations of our study must be noted. First, the quality of some included studies was low. Random allocation and blinding of participants, researchers, and outcome assessments were observed only in six and four included studies, respectively. Second, present review was not registered in any registration databases. Third, since some studies had not determined the basic serum/plasma level of Zn in study population, subgroup analysis based on basic Zn level was not performed. Fourth, as study population of included studies were different, we used random effect model to control unobserved heterogeneity. However, random effect model does not generalise the results of the performed meta-analysis to real-world situations(Reference Ades, Lu and Higgins60). Fifth, because of limited number of studies on IL-2, subgroup analysis and meta-regression were not possible. Therefore, sources of heterogeneity were unknown and this question the generalisability of our result on IL-2. Sixth, we could not include studies on other inflammatory markers. There are a variety of inflammatory cytokines like IL-1 and IL-8 which we included in our search regimen. However, because of the limited number of studies on each, meta-analysis on them was impossible. Other trial studies on the other inflammatory markers are needed to find a comprehensive conclusion about the effect of Zn on the inflammatory process.

There are some strengths in our meta-analysis. First, it is the first comprehensive meta-analysis study which evaluated the effect of Zn supplementation on the inflammatory cytokines. Second, we analysed the included studies based on different subgroups to find a defined conclusion. Third, we assessed all included studies with appropriate tests to find any source of heterogeneity and bias between the studies.

Conclusion

Zn supplementation can decrease IL-6 serum/plasma level. Zn has no significant effects on IL-2 and TNF-α production. Lower dosage of zinc gluconate has ameliorative effect on TNF-α serum/plasma level. Dosage and form of Zn supplement are two key factors in the effectiveness of Zn supplementation in modifying inflammatory responses. A dosage lower than upper intake level of zinc gluconate seems to have a better effect on inflammatory markers.

Acknowledgements

The research protocol was approved by Vice Chancellor for Research (VCR), Tabriz University of Medical Sciences (registration code: 64693).

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Conceptualisation: A. H. F. and B. A. Database searching: M. Z., A. H. F. and Y. K. B. Screening: O. M. T.-R., E. F. and M. A. Data extraction: A. H. F. and L. P. Drafting of the paper: A. H. F. and Y. K. B. Statistical analysis: M. Z. Critical revision: B. B., A. K. and B. A. All the authors approved the final version to be submitted.

The authors declare that there are no conflicts of interest.

References

Ahmed, AU (2011) An overview of inflammation: mechanism and consequences. Front Biol 6, 274.CrossRefGoogle Scholar
McLoughlin, RF, Berthon, BS, Jensen, ME, et al. (2017) Short-chain fatty acids, prebiotics, synbiotics, and systemic inflammation: a systematic review and meta-analysis. Am J Clin Nutr 106, 930945.CrossRefGoogle ScholarPubMed
Grivennikov, SI, Greten, FR & Karin, M (2010) Immunity, inflammation, and cancer. Cell 140, 883899.CrossRefGoogle ScholarPubMed
Schwingshackl, L & Hoffmann, G (2014) Mediterranean dietary pattern, inflammation and endothelial function: a systematic review and meta-analysis of intervention trials. Nutr Metab Cardiovasc Dis 24, 929939.CrossRefGoogle ScholarPubMed
Zhang, J-M & An, J (2007) Cytokines, inflammation and pain. Int Anesthesiol Clin 45, 27.CrossRefGoogle ScholarPubMed
Derosa, G, Maffioli, P, Simental-Mendia, LE, et al. (2016) Effect of curcumin on circulating interleukin-6 concentrations: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 111, 394404.CrossRefGoogle ScholarPubMed
Coussens, LM & Werb, Z (2002) Inflammation and cancer. Nature 420, 860867.CrossRefGoogle ScholarPubMed
Parameswaran, N & Patial, S (2010) Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryotic Gene Expression 20, 87103.CrossRefGoogle ScholarPubMed
Banchereau, J, Pascual, V & O’Garra, A (2012) From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol 13, 925931.CrossRefGoogle ScholarPubMed
Tanaka, T, Narazaki, M & Kishimoto, T (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6, a016295.CrossRefGoogle ScholarPubMed
Vaeth, M & Feske, S (2018) NFAT control of immune function: new Frontiers for an Abiding Trooper. F1000Res 7, 260.CrossRefGoogle ScholarPubMed
Liu, T, Zhang, L, Joo, D, et al. (2017) NF-κB signaling in inflammation. Signal Transduction Targeted Ther 2, 17023.CrossRefGoogle ScholarPubMed
Berberich-Siebelt, F, Klein-Hessling, S, Hepping, N, et al. (2000) C/EBPbeta enhances IL-4 but impairs IL-2 and IFN-gamma induction in T cells. Eur J Immunol 30, 25762585.3.0.CO;2-N>CrossRefGoogle ScholarPubMed
Luo, Y & Zheng, SG (2016) Hall of fame among pro-inflammatory cytokines: interleukin-6 gene and its transcriptional regulation mechanisms. Front Immunol 7, 604.CrossRefGoogle Scholar
Cassandri, M, Smirnov, A, Novelli, F, et al. (2017) Zinc-finger proteins in health and disease. Cell Death Discov 3, 17071.CrossRefGoogle ScholarPubMed
Bao, B, Prasad, AS, Beck, FWJ, et al. (2007) Zinc up-regulates NF-κB activation via phosphorylation of IκB in HUT-78 (Th0) cells. FEBS Lett 581, 45074511.CrossRefGoogle ScholarPubMed
Mackenzie, GG & Oteiza, PI (2007) Zinc and the cytoskeleton in the neuronal modulation of transcription factor NFAT. J Cell Physiol 210, 246256.CrossRefGoogle ScholarPubMed
Herbein, G, Varin, A & Fulop, T (2006) NF-kappaB, AP-1, zinc-deficiency and aging. Biogerontology 7, 409419.CrossRefGoogle ScholarPubMed
Kim, MH, Aydemir, TB & Cousins, RJ (2016) Dietary zinc regulates apoptosis through the phosphorylated eukaryotic initiation factor 2α/activating transcription factor-4/C/EBP-homologous protein pathway during pharmacologically induced endoplasmic reticulum stress in livers of mice. J Nutr 146, 21802186.CrossRefGoogle ScholarPubMed
Jamilian, M, Foroozanfard, F, Bahmani, F, et al. (2016) Effects of zinc supplementation on endocrine outcomes in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Biol Trace Elem Res 170, 271278.CrossRefGoogle ScholarPubMed
Khazdouz, M, Mazidi, M, Ehsaei, M-R, et al. (2018) Impact of zinc supplementation on the clinical outcomes of patients with severe head trauma: a double-blind randomized clinical trial. J Diet Suppl 15, 110.CrossRefGoogle ScholarPubMed
Cruz, KJC, de Oliveira, ARS & do Nascimento Marreiro, D (2015) Antioxidant role of zinc in diabetes mellitus. World J Diabetes 6, 333.CrossRefGoogle ScholarPubMed
Dias, PCS, Sena-Evangelista, KCM, de Oliveira Paiva, MSM, et al. (2014) The beneficial effects of rosuvastatin are independent of zinc supplementation in patients with atherosclerosis. J Trace Elem Med Biol 28, 194199.CrossRefGoogle ScholarPubMed
Moher, D, Liberati, A, Tetzlaff, J, et al. (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med 3, e123e130.Google ScholarPubMed
Higgins, JPT, Altman, DG, Gøtzsche, PC, et al. (2011) The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343, d5928.CrossRefGoogle ScholarPubMed
Higgins, JPT, Thompson, SG, Deeks, JJ, et al. (2003) Measuring inconsistency in meta-analyses. BMJ 327, 557560.CrossRefGoogle ScholarPubMed
Begg, CB & Mazumdar, M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 10881101.CrossRefGoogle Scholar
Egger, M, Davey Smith, G, Schneider, M, et al. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629634.CrossRefGoogle ScholarPubMed
Ranjbar, E, Shams, J, Sabetkasaei, M, et al. (2014) Effects of zinc supplementation on efficacy of antidepressant therapy, inflammatory cytokines, and brain-derived neurotrophic factor in patients with major depression. Nutr Neurosci 17, 6571.CrossRefGoogle ScholarPubMed
Khorsandi, H, Nikpayam, O, Yousefi, R, et al. (2019) Zinc supplementation improves body weight management, inflammatory biomarkers and insulin resistance in individuals with obesity: a randomized, placebo-controlled, double-blind trial. Diabetol Metab Syndr 11, 101.CrossRefGoogle ScholarPubMed
Pourteymour, FTF, Valipoor, B, Ostadrahimi, A, et al. (2011) Effect of zinc supplementation on inflammatory markers in women with polycystic ovary syndrome. Shiraz E Med J 12, 3038.Google Scholar
Roshanravan, N, Tarighat-Esfanjani, A, Alamdari, NM, et al. (2018) The effects of zinc supplementation on inflammatory parameters in pregnant women with impaired glucose tolerance: a randomized placebo controlled clinical trial. Prog Nutr 20, 330336.Google Scholar
Kara, E, Ozal, M, Gunay, M, et al. (2011) Effects of exercise and zinc supplementation on cytokine release in young wrestlers. Biol Trace Elem Res 143, 14351440.CrossRefGoogle ScholarPubMed
de Moura, MSB, Soares, NRM, de Lima Barros, , et al. (2020) Zinc gluconate supplementation impacts the clinical improvement in patients with ulcerative colitis. BioMetals 33, 1527.CrossRefGoogle ScholarPubMed
Freiberg, MS, Cheng, DM, Gnatienko, N, et al. (2020) Effect of zinc supplementation vs placebo on mortality risk and HIV disease progression among HIV-positive adults with heavy alcohol use: a randomized clinical trial. JAMA Network Open 3, e204330.CrossRefGoogle ScholarPubMed
Foster, M, Petocz, P & Samman, S (2013) Inflammation markers predict zinc transporter gene expression in women with type 2 diabetes mellitus. J Nutr Biochem 24, 16551661.CrossRefGoogle ScholarPubMed
Meksawan, K, Sermsri, U & Chanvorachote, P (2014) Zinc supplementation improves anticancer activity of monocytes in type-2 diabetic patients with metabolic syndrome. Anticancer Res 34, 295299.Google ScholarPubMed
Bao, B, Prasad, AS, Beck, FW, et al. (2010) Zinc decreases C-reactive protein, lipid peroxidation, and inflammatory cytokines in elderly subjects: a potential implication of zinc as an atheroprotective agent. Am J Clin Nutr 91, 16341641.CrossRefGoogle ScholarPubMed
Kim, J & Ahn, J (2014) Effect of zinc supplementation on inflammatory markers and adipokines in young obese women. Biol Trace Elem Res 157, 101106.CrossRefGoogle ScholarPubMed
Suliburska, J, Skrypnik, K, Szulińska, M, et al. (2018) Effect of hypotensive therapy combined with modified diet or zinc supplementation on biochemical parameters and mineral status in hypertensive patients. J Trace Elem Med Biol 47, 140148.CrossRefGoogle ScholarPubMed
Mousavi, SM, Djafarian, K, Mojtahed, A, et al. (2018) The effect of zinc supplementation on plasma C-reactive protein concentrations: A systematic review and meta-analysis of randomized controlled trials. Eur J Pharmacol 834, 1016.CrossRefGoogle ScholarPubMed
Sapota, A, Daragó, A, Skrzypińska-Gawrysiak, M, et al. (2014) The bioavailability of different zinc compounds used as human dietary supplements in rat prostate: a comparative study. Biometals 27, 495505.CrossRefGoogle ScholarPubMed
Zhang, S-Q, Yu, X-F, Zhang, H-B, et al. (2018) Comparison of the oral absorption, distribution, excretion, and bioavailability of zinc sulfate, zinc gluconate, and zinc-enriched yeast in rats. Mol Nutr Food Res 62, 1700981.CrossRefGoogle ScholarPubMed
Institute of Medicine (US) Panel on Micronutrients (2001)Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academies Press.Google Scholar
Lee, SR (2018) Critical role of zinc as either an antioxidant or a prooxidant in cellular systems. Oxid Med Cell Longev 2018, 9156285.CrossRefGoogle ScholarPubMed
Plum, LM, Rink, L & Haase, H (2010) The essential toxin: impact of zinc on human health. Int J Environ Res Public Health 7, 13421365.CrossRefGoogle ScholarPubMed
Prasad, AS, Beck, FW, Kaplan, J, et al. (1999) Effect of zinc supplementation on incidence of infections and hospital admissions in sickle cell disease (SCD). Am J Hematol 61, 194202.3.0.CO;2-C>CrossRefGoogle ScholarPubMed
Kloubert, V, Wessels, I, Wolf, J, et al. (2020) Zinc deficiency leads to reduced interleukin-2 production by active gene silencing due to enhanced CREMα expression in T cells. Clin Nutr (epublication ahead of print version 30 October 2020).Google ScholarPubMed
Hoyer, KK, Dooms, H, Barron, L, et al. (2008) Interleukin-2 in the development and control of inflammatory disease. Immunol Rev 226, 1928.CrossRefGoogle ScholarPubMed
Shachar, I & Karin, N (2013) The dual roles of inflammatory cytokines and chemokines in the regulation of autoimmune diseases and their clinical implications. J Leukoc Biol 93, 5161.CrossRefGoogle ScholarPubMed
Rahfiludin, MZ, Wirjatmadi, B, Agusni, I, et al. (2011) Zinc supplementation could modulate T cell to maintain interleukin-2 level in seropositive contact of leprosy patients. Med J Indones 20, 201204.CrossRefGoogle Scholar
Prasad, AS, Bao, B, Beck, FW, et al. (2004) Antioxidant effect of zinc in humans. Free Radic Biol Med 37, 11821190.CrossRefGoogle ScholarPubMed
Mizgerd, JP, Spieker, MR & Doerschuk, CM (2001) Early response cytokines and innate immunity: essential roles for TNF receptor 1 and type I IL-1 receptor during Escherichia coli pneumonia in mice. J Immunol 166, 40424048.CrossRefGoogle ScholarPubMed
Andreasen, AS, Krabbe, KS, Krogh-Madsen, R, et al. (2008) Human endotoxemia as a model of systemic inflammation. Curr Med Chem 15, 16971705.CrossRefGoogle Scholar
Giuliani, C, Bucci, I & Napolitano, G (2018) The role of the transcription factor nuclear factor-kappa B in thyroid autoimmunity and cancer. Front Endocrinol (Lausanne) 9, 471.CrossRefGoogle ScholarPubMed
Faghfouri, AH, Zarrin, R, Maleki, V, et al. (2020) A comprehensive mechanistic review insight into the effects of micronutrients on toll-like receptors functions. Pharmacol Res 152, 104619.CrossRefGoogle ScholarPubMed
Hu, L, Cheng, S, Li, Y, et al. (2018) Chitosan–Zn chelate downregulates TLR4-NF-κB signal pathway of inflammatory response and cell death-associated proteins compared to inorganic zinc. Biol Trace Elem Res 184, 9298.CrossRefGoogle ScholarPubMed
Bao, B, Prasad, AS, Beck, FWJ, et al. (2003) Zinc modulates mRNA levels of cytokines. Am J Physiol Endocrinol Metab 285, E1095E1102.CrossRefGoogle ScholarPubMed
Cousins, RJ (1998) A role of zinc in the regulation of gene expression. Proc Nutr Soc 57, 307311.CrossRefGoogle ScholarPubMed
Ades, AE, Lu, G & Higgins, JP (2005) The interpretation of random-effects meta-analysis in decision models. Med Decis Making 25, 646654.CrossRefGoogle ScholarPubMed
Figure 0

Fig. 1. The process of study selection through stages shown by Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) flow chart. RCT, randomised controlled trial.

Figure 1

Table 1. Characteristics and baseline measurements of included studies(Mean values and standard deviations)

Figure 2

Fig. 2. The result of risk of bias assessment using Cochrane Collaboration’s risk of bias tool: each risk of bias item for included studies (green (+) means low risk of bias, yellow (?) means unclear risk of bias, red (−) means high risk of bias).

Figure 3

Fig. 3. Forest plot (a) detailing standardised mean differences (SMD) and 95 % confidence intervals and funnel plot (b) displaying publication bias in the studies reporting the effects of zinc supplementation on TNF-α level.

Figure 4

Table 2. Pooled estimates of effects of zinc on inflammatory markers within different subgroups(Standard mean differences (SMD) and 95 % confidence intervals)

Figure 5

Fig. 4. Forest plot (a) detailing standardised mean differences (SMD) and 95 % confidence intervals and funnel plot (b) displaying publication bias in the studies reporting the effects of zinc supplementation on IL-2 level.

Figure 6

Fig. 5. Forest plot (a) detailing standardised mean differences (SMD) and 95 % confidence intervals and funnel plot (b) displaying publication bias in the studies reporting the effects of zinc supplementation on IL-6 level.